Stock Analiz

Nyxoah SA NYXH

Medical/Dental Instruments · IPO 2021 · data as of November 13, 2026

$0.90Market cap $90M
Open the interactive analysis →

Nyxoah SA (NYXH) is a healthcare company listed in the US with a market value of about $90M. In fiscal year 2025 it had revenue of $12M and net income of -$106M, a net margin of -899.1%.

Its overall Stock Analiz score is 1.8 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 168% a year, a 5-year average ROIC of -51%.

About Nyxoah SA

Nyxoah SA is listed in the US and classified in medical/dental instruments, IPO year 2021. Revenue went from $84670 in 2020 to $12M in 2025, growth of about 168.3% a year. It was profitable in 0 of the last 6 years in our data.

Score: 1.8 / 5

Value0/5
Future growth4/5
Track record1/5
Financial health4/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year
  • More cash than debt, or low debt to equity
  • Interest covered more than 5 times
  • Debt below 3 years of free cash flow

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year
  • 5-year average ROIC above 12%

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S7.6
P/B1.6
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-91.1%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)150.7%
Revenue growth (5 yrs, per year)168.3%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-1491.5%
ROIC (5-yr avg.)-51.0%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 6 years

Fiscal year202520242023202220212020
Revenue$12M$5M$5M$3M$964980$84670
Net income-$106M-$62M-$48M-$33M-$31M-$15M
Free cash flow-$82M-$52M-$52M-$32M-$30M-$9M
EPS (diluted)$-1.06$-0.61$-0.48$-0.33$-0.31$-0.15
Net margin-899.1%-1310.2%-993.8%-1012.5%-3241.7%-17746.4%
ROIC-134.2%-41.0%-44.5%-21.3%-14.0%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does Nyxoah SA pay a dividend?

Not currently.

Is Nyxoah SA a good stock to buy?

We do not give buy or sell advice. Nyxoah SA scores 1.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.